Thus, this work challenged the general routine of activating antitumor immunity using DCs as APCs58,59, and efficiently overcame major limitations of anti-PD-1 therapy by reprogramming TAMs highly enriched in tumor tissues. The gene discussed is PDCD1; the disease is neoplasm.